Data

Developing Alternative Treatments for Young People with Depression: A study of transcranial alternating current stimulation (tACS).

Monash University

Dataset description

tACS treatment frequency will be determined during an EEG recording (see EEG assessment section below for details on EEG recording equipment). During the EEG recording, the N-back working memory task will be administered to participants to elicit theta oscillations, and the Sternberg working memory task will be administered to elicit alpha oscillations. Stimulation frequency will then be set to each individual’s theta and alpha frequency measurements, depending on the treatment allocated. The current of tACS delivered 48,000 cycles (i.e. 20 mins) with no DC current offset. The current ramps gently over a period of e.g. 5-10 seconds to the desired peak for patient comfort. The stimulator fade in and fade out was specified to 100 cycles at the beginning and end of stimulation. A pair of 5x5cm electrodes placed within saline soaked sponges and a purpose-built battery-driven constant stimulator will deliver the current. The electrodes will be placed over the left pre-frontal cortex on F5 and, over the right pre-frontal cortex on F6, located using the 10-20 EEG position. This electrode montage has been modelled to show a reasonably widespread current flow through fronto-central cortical and frontal subcortical regions.
Click to explore relationships graph

Source Study

Purpose

Treatment

Phase

Not Applicable

Funding

Charities/Societies/Foundations,Perpetual Foundation IMPACT Philanthropy Program

Scientific enquiries

Dr Manreena Kaur

Brief Summary

This study aims to test the effectiveness of Transcranial Alternating Current Stimulation (tACS), a gentle non-invasive brain stimulation technique, in treating young people (16-30 years old) with depression. Participants will be randomised into three groups; theta tACS, alpha tACS or sham stimulation and will receive 30 treatment sessions over four-weeks. Depressive symptoms and cognition will be assessed pre-treatment, mid-treatment phase, post-treatment and at 3 month follow-up. It is anticip ....
Read more

Key Inclusion Criteria

-Diagnosis of major depressive episode (MDE), in accordance with the Mini International Neuropsychiatric Interview - Individuals between 16 to 30 years of age - Depression severity quantified using the Montgomery-Asberg Depression Rating Scale (MADRS) cut-off scores (mild: 7-19; moderate: 20-34; severe: >34) - No more than 2 previously received adequate trials of antidepressant treatment - Demonstrated capacity to give informed consent

Key Exclusion Criteria

-Inability to give informed consent -DSM V diagnoses of a psychotic disorder or current substance-use disorders; -Developmental disorders (including autism); -History of sustained head injury; -Other neurological illness; -Intellectual disability; -Major medical illness impacting brain function -Pregnancy

Can healthy volunteers participate?

No

 

Population

Sample Size    55

Min. age    16 Years

Max. age    30 Years

Sex    Both males and females

Condition category    Early stage Depression

Condition code    Mental Health

Intervention

Intervention code Treatment: Devices

tACS treatment frequency will be determined during an EEG recording (see EEG assessment section below for details on EEG recording equipment). During the EEG recording, the N-back working memory task will be administered to participants to elicit theta oscillations, and the Sternberg working memory task will be administered to elicit alpha oscillations. Stimulation frequency will then be set to each individual’s theta and alpha frequency measurements, depending on the treatment allocated. The cu ....
Read more

Comparison

Control group Placebo

Sham protocol: Sham stimulation is achieved by applying a period of 2 minutes of tACS at 13 Hz (i.e. a low beta frequency) with a 10 second ramp on and 10 second ramp off to provide the participant an experience of stimulation. The switching off of the stimulation pre-programmed within the software of the device. The participant will just turn the device on for 20 minutes without any indication of the type of stimulation. There is no evidence that the brief 120 second period of stimulation produ ....
Read more

Outcomes

Outcome: Changes in severity of depressive symptoms as measured by change in Montgomery-Asberg Depression Rating Scale (MADRS) scores.
Timepoint: Baseline, 4 weeks (end-point)

Outcome: Changes in severity of depressive symptoms as measured by change in Beck Depression Inventory (BDI) scores.
Timepoint: Baseline, 4 weeks (end-point)

Outcome: Changes in severity of depressive symptoms as measured by change in Five Facet Mindfulness Questionnaire (FFMQ) scores.
Timepoint: Baseline, 4 weeks (end-point)

Study Protocol: Not Available
Data Dictionary: Not Available

Will individual participant data (IPD) for this trial be available?

yes

What data in particular will be shared?

The data set will be shared, in de-identified form only.

When will data be available?

Available following publication, and no end date determined.

Available to whom?

Available on a case-by-case basis at the discretion of the Principal Investigator, dependent on the proposal and methods of those wishing to access.

Available for what types of analyses?

Dependent on the proposal and methods of those wishing to access.

Source study information is derived from the Australian New Zealand Clinical Trials Registry (ANZCTR). For more information on the ANZCTR, please see anzctr.org.au